BPC-157 and TB-500 Dosage Protocol BPC-157: 250500mcg daily, injected subcutaneously near the injury site TB-500: 22.5mg twice weekly (loading phase) for 46 weeks, then 2mg once weekly (maintenance phase) The combination is typically used for 612 weeks, depending on injury severity and healing progress
Killed vaccines are recommended
BPC-157 + NAD+ cellular repair + energy metabolism studies
Realistic expectations: Peptides unlikely producing dramatic bone density improvements matching pharmaceutical osteoporosis drugs
No study has shown BPC-157 promoting tumor growth, but the concern is noted in reviews (Sikiric et al., 2014) FDA status -- added to restricted compounding list in 2024
Two people using identical protocols may have completely different results simply because one received genuine product while the other received degraded, contaminated, or counterfeit material